BioNTech SE - Asset Resilience Ratio

Latest as of March 2026: 22.30%

BioNTech SE (22UA) has an Asset Resilience Ratio of 22.30% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 22UA strategic asset allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets

€4.70 Billion

≈ $5.49 Billion USD Cash + Short-term Investments

Total Assets

€21.07 Billion

≈ $24.64 Billion USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how BioNTech SE's Asset Resilience Ratio has changed over time. See debt-free asset ratio of BioNTech SE to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down BioNTech SE's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 22UA company net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€4.70 Billion	22.3%
Total Liquid Assets	€4.70 Billion	22.30%

Asset Resilience Insights

Good Liquidity Position: BioNTech SE maintains a healthy 22.30% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

BioNTech SE Industry Peers by Asset Resilience Ratio

Compare BioNTech SE's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Samsung Biologics Co Ltd KO:207940	Biotechnology	5.66%
Royalty Pharma Plc NASDAQ:RPRX	Biotechnology	0.11%
Abivax SA PA:ABVX	Biotechnology	2.34%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
HLB Co. Ltd KQ:028300	Biotechnology	0.72%
Chongqing Zhifei Bio Products SHE:300122	Biotechnology	-0.08%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Theravance Biopharma Inc F:0TB	Biotechnology	37.29%

Annual Asset Resilience Ratio for BioNTech SE (2016–2025)

The table below shows the annual Asset Resilience Ratio data for BioNTech SE.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	32.75%	€7.20 Billion ≈ $8.42 Billion	€21.99 Billion ≈ $25.71 Billion	+1.59pp
2024-12-31	31.17%	€7.02 Billion ≈ $8.21 Billion	€22.53 Billion ≈ $26.34 Billion	+9.93pp
2023-12-31	21.23%	€4.89 Billion ≈ $5.71 Billion	€23.01 Billion ≈ $26.90 Billion	+20.42pp
2022-12-31	0.81%	€189.40 Million ≈ $221.43 Million	€23.28 Billion ≈ $27.22 Billion	-1.60pp
2021-12-31	2.41%	€381.60 Million ≈ $446.13 Million	€15.83 Billion ≈ $18.51 Billion	-3.51pp
2020-12-31	5.92%	€137.23 Million ≈ $160.44 Million	€2.32 Billion ≈ $2.71 Billion	+5.71pp
2019-12-31	0.21%	€1.68 Million ≈ $1.96 Million	€797.65 Million ≈ $932.53 Million	+0.16pp
2018-12-31	0.05%	€336.00K ≈ $392.82K	€652.99 Million ≈ $763.41 Million	-0.01pp
2017-12-31	0.07%	€246.00K ≈ $287.60K	€374.71 Million ≈ $438.08 Million	-0.33pp
2016-12-31	0.39%	€1.53 Million ≈ $1.79 Million	€389.96 Million ≈ $455.90 Million	--

pp = percentage points

About BioNTech SE

F:22UA Germany Biotechnology

Market Cap

$23.08 Billion

€19.74 Billion EUR

Market Cap Rank

#1304 Global

#286 in Germany

Share Price

€78.05

Change (1 day)

+0.39%

52-Week Range

€72.05 - €102.20

All Time High

€377.00